Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer

Inclusion Criteria: * Histologically proven, locally advanced stage III-IV A-B (UICC 2002) primary squamous cell carcinoma of the oral cavity, the oropharynx, the hypopharynx, the supraglottic larynx * Age ≥ 18 * Written informed consent for the participation in the clinical trial Exclusion Criteria: * Inadequate hepatic function: Bilirubin \> 2,0 mg/dl, SGOT, SGPT, AP, Gamma-GT \> 3 x ULN * Inadequate bone marrow function: leukocytes \< 3,5 x 10\^9/l, platelets \< 100 x 10\^9/l or neutrophils \< 1,5 x 10\^9/l * Serum creatinine \> 1,5 mg/dl, creatinine clearance \< 60ml/min * Uncontrolled severe somatic or psychological disease: e.g. unstable angina pectoris; myocardial infarction during the last 6 months; significant cardial rhythm disorders; apoplexy; high grade stenosis of the carotis; neurological or psychiatric disorders including convulsive disorders; dementia; psychosis; active uncontrolled infection or sepsis; liver cirrhosis; Child stage B,C; severe liver function disorders; marginal changes in the blood count; severe kidney damage; HIV-infection * Acute infections * Fertile women without adequate contraception during and up to 6 months after therapy (the method of contraception has to be high effective as described in the Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95 mod) and it has to be discussed with the investigator) * Pregnant or breast feeding women * Men, who are not willing to use adequate contraception during and up to 6 months after therapy, that is discussed with the investigator * ECOG-Status \> 1 * Reduced hearing function (especially higher frequencies) * Exsiccosis * Neuropathy, caused by cisplatin * Concurrent malignancies, with exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma or the cervix * Prior radiotherapy of the neck or chemotherapy * Distant metastasis * Recurrent carcinoma in the head and neck region * Prior neck-dissection or surgical intervention exceeding an exploratory excision * Known intolerance to 5-Fluorouracil * Known deficit of Dihydropyrimidine dehydrogenase (DPD) * Simultaneous therapy with Brivudin or other inhibitors of DPD * Known intolerance to Cisplatin or other substances that contain platin * Known intolerance to Paclitaxel or one of the included substances, especially to Poly(oxyethylene)Rhizinusöl/Macrogolglycerol ricinoleate